Non Small Cell Lung Cancer

P=N/A, N=150, Recruiting, Antalya Training and Research Hospital

P=N/A, N=90, Recruiting, Sunshine Coast University Hospital | Not yet recruiting --> Recruiting

P2, N=180, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting

Human bronchial epithelial tumor cell (HBEC) lines H2030, H2030-BrM3, and H1299, with or without NDR2 depletion via siRNA or shRNA, were cultured for up to 24 h in the presence or absence of serum, and with or without the autophagosome-lysosome fusion inhibitor chloroquine (CQ)...Unlike NDR1, NDR2 is stabilized under starvation and promotes autophagy by regulating LC3 and ATG9A, thereby supporting NSCLC cell proliferation and migration. Routine staining for NDR2 and/or ATG9 could aid in diagnosing NSCLC with high migratory potential.

Short course preoperative nivolumab with or without relatlimab showed encouraging efficacy and survival outcomes, which compare favorably with chemo-immunotherapy-based perioperative treatment regimens.

Inhibition of NET formation by DNase effectively suppressed tumor progression and immune evasion. Altogether, our findings indicate that in LUAD, NETs or NF-κB pathways collaborate to enhance their roles in the tumor process and may represent a promising therapeutic target.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer worldwide. In this retrospective cohort study we examined how patient and tumor characteristics influences NSCLC treatment in Romania, Bulgaria, and Serbia, and revealed significant regional differences in baseline characteristics, treatment preferences, and influencing factors for stage IV NSCLC in these countries.

Treatment with the PI3K inhibitor LY294002 produced changes consistent with those observed upon YBX1 silencing. In a subcutaneous xenograft mouse model, YBX1 silencing was associated with reduced tumor growth and ferroptosis-related changes, effects that were partially reversed by EGF treatment. These findings suggest that YBX1 is associated with ferroptosis-related changes and altered proliferation and migration in A549 cells, potentially involving PI3K/AKT/mTOR signaling, highlighting YBX1 as a potential therapeutic target.

Analysis of the available studies indicated that 18F-FDG PET/CT based radiomics features showed a moderate diagnostic performance for prediction of PD-L1 expression in NSCLC. However, future studies would be necessary for standardization of the method for prediction of PD-L1 expression in NSCLC using 18F-FDG PET/CT based radiomics features.

The nomogram constructed by ER score and clinical features showed good predictive performance on LUAD. This study provided new insights into understanding the role of ER stress in LUAD.

For instance, a recent phase II study of nivolumab rechallenge in non-small cell lung cancer patients who relapsed after an initial response reported a modest ORR of 8.5%...Although major guidelines recommend permanent discontinuation for severe (Grade ≥ 3) irAEs, emerging evidence-including class-switching strategies and organ-specific prophylaxis-suggests that rechallenge may be feasible in selected patients. A personalized risk-benefit assessment remains essential, considering the type and severity of the initial irAE and the reason for discontinuation.